Reuters: Hot Stocks: Merck KGaA to continue testing cancer vaccine

Reuters: Hot Stocks Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Free Bestselling eBooks It's easy: sign up in under 10 seconds, tell us what kind of eBooks you love & we'll email you a list of deals every day - FREE! Join now! From our sponsors

Merck KGaA to continue testing cancer vaccine Sep 25th 2013, 05:46 FRANKFURT, Sept 25 | Wed Sep 25, 2013 1:46am EDT FRANKFURT, Sept 25 (Reuters) - Germany's Merck KGaA said it would start a new study testing its experimental lung cancer vaccine Stimuvax, which fell through in a previous late-stage trial. Merck said on Tuesday it would test the drug, which it licensed from U.S. biotech firm Oncothyreon, on patients with locally advanced Stage III non-small cell lung cancer (NSCLC), which cannot be surgically removed. Stimuvax, also known as Tecemotide, failed to improve survival in a pivotal study in December, dealing a blow to the company and the high-risk field of using vaccines to fight tumours. Merck said on Tuesday that data from an analysis of a predefined patient subgroup in this trial, however, showed some promise. (Reporting by Ludwig Burger)

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions